Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.

Cells lacking the tumor suppressor gene LKB1/STK11 alter their metabolism to match the demands of accelerated growth, leaving them highly vulnerable to stress. However, targeted therapy for LKB1-deficient cancers has yet to be reported. In both Kras/p53/Lkb1 cell lines and a genetically engineered mouse model of Kras/p53/Lkb1-induced lung cancer, much higher rates of DNA damage occur, resulting in increased dependence on Chk1 checkpoint function. Here we demonstrate that short-term treatment with the Chk1 inhibitor AZD7762 reduces metabolism in pembrolizumab tumors, synergizing with the DNA-damaging drug gemcitabine to reduce tumor size in these models. Our results offer preclinical proof of concept for use of a Chk1 inhibitor to safely enhance the efficacy of gemcitabine, particularly in aggressive KRAS-driven LKB1-deficient lung adenocarcinomas. Cancer Res; 77(18); 5068-76. ©2017 AACR.

[1]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Sathesh Bhat,et al.  Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small cell lung cancer in preclinical models , 2016, Nature Medicine.

[3]  Gordon B. Mills,et al.  Cardiac glycosides display selective efficacy for STK11 mutant lung cancer , 2016, Scientific Reports.

[4]  D. Planchard,et al.  ALK inhibitors in non-small cell lung cancer: the latest evidence and developments , 2016, Therapeutic advances in medical oncology.

[5]  T. Helleday,et al.  Targeting DNA repair, DNA metabolism and replication stress as anti‐cancer strategies , 2016, The FEBS journal.

[6]  A. Kung,et al.  18F-FDG-PET/CT imaging of drug-induced metabolic changes in genetically engineered mouse lung cancer models. , 2015, Cold Spring Harbor Protocols.

[7]  Gisele Monteiro,et al.  Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. , 2014, European journal of pharmacology.

[8]  N. Tran,et al.  LKB1 inactivation sensitizes non-small cell lung cancer to pharmacological aggravation of ER stress. , 2014, Cancer letters.

[9]  William Pao,et al.  AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.

[10]  D. Carbone,et al.  LKB1 Loss Induces Characteristic Patterns of Gene Expression in Human Tumors Associated with NRF2 Activation and Attenuation of PI3K-AKT , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  Takla Griss,et al.  Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α , 2014, Proceedings of the National Academy of Sciences.

[12]  E. Sausville,et al.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[13]  A. Eastman,et al.  The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design. , 2013, British journal of clinical pharmacology.

[14]  Travis J Cohoon,et al.  Metabolic and functional genomic studies identify deoxythymidylate kinase as a target in LKB1-mutant lung cancer. , 2013, Cancer discovery.

[15]  Xiaojin Shi,et al.  Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours , 2013, Cancer Chemotherapy and Pharmacology.

[16]  Liu Wei,et al.  LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. , 2013, Cancer cell.

[17]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[18]  C. Perou,et al.  LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. , 2012, Cancer cell.

[19]  Navdeep S. Chandel,et al.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress , 2012, Nature.

[20]  D. Hardie,et al.  AMPK: a nutrient and energy sensor that maintains energy homeostasis , 2012, Nature Reviews Molecular Cell Biology.

[21]  Andrew L. Kung,et al.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response , 2012, Nature.

[22]  R. Shaw,et al.  The AMPK signalling pathway coordinates cell growth, autophagy and metabolism , 2011, Nature Cell Biology.

[23]  M. Garrett,et al.  Anticancer therapy with checkpoint inhibitors: what, where and when? , 2011, Trends in pharmacological sciences.

[24]  B. Viollet,et al.  Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy , 2011, Science.

[25]  K. Nakagawa,et al.  Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer , 2011, Clinical Medicine Insights. Oncology.

[26]  J. Neal,et al.  Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh , 2010, Current treatment options in oncology.

[27]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[28]  Chin-Lee Wu,et al.  mTOR and HIF-1α-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome , 2009, Proceedings of the National Academy of Sciences.

[29]  Kwok-Kin Wong,et al.  Somatic LKB1 Mutations Promote Cervical Cancer Progression , 2009, PloS one.

[30]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[31]  B. Turk,et al.  AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.

[32]  J. Minna,et al.  Prevalence and specificity of LKB1 genetic alterations in lung cancers , 2007, Oncogene.

[33]  D. Neil Hayes,et al.  LKB1 modulates lung cancer differentiation and metastasis , 2007, Nature.

[34]  B. Kaina,et al.  DNA damage-induced cell death by apoptosis. , 2006, Trends in molecular medicine.

[35]  E. Mini,et al.  Cellular pharmacology of gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  K. Inoki,et al.  TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival , 2003, Cell.

[37]  David Sidransky,et al.  Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. , 2002, Cancer research.

[38]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  D. Carbone,et al.  A Transcriptional Signature Identifies LKB1 Functional Status as a Novel Determinant of MEK Sensitivity in Lung Adenocarcinoma. , 2017, Cancer research.

[40]  Irene V. Bijnsdorp,et al.  Analysis of drug interactions. , 2011, Methods in molecular biology.

[41]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.